Esmo Open, Esmo Open, 4(1), p. e000079, 2016
DOI: 10.1136/esmoopen-2016-000079
Full text: Download
We report the clinical and molecular characteristics of a 69-year-old woman with metastatic colorectal cancer, treated with the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody panitumumab, displaying peculiar molecular tumour heterogeneity at progression consisting of KRAS and MET amplification as distinct drivers associated with acquired resistance.